122 related articles for article (PubMed ID: 35790691)
41. Usefulness of FDG PET/CT derived parameters in prediction of histopathological finding during the surgery in patients with pancreatic adenocarcinoma.
Myssayev A; Myssayev A; Ideguchi R; Eguchi S; Adachi T; Sumida Y; Tobinaga S; Uetani M; Kudo T
PLoS One; 2019; 14(1):e0210178. PubMed ID: 30629646
[TBL] [Abstract][Full Text] [Related]
42. Volumetric PET parameters can predict overall survival in advanced lung adenocarcinoma.
Yanarateş A; Yazici B
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):3-8. PubMed ID: 31818695
[TBL] [Abstract][Full Text] [Related]
43. Prognostic Value of
Albano D; Camoni L; Giubbini R; Bertagna F
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e897-e904. PubMed ID: 32703751
[TBL] [Abstract][Full Text] [Related]
44. Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from
Schmidkonz C; Krumbholz M; Atzinger A; Cordes M; Goetz TI; Prante O; Ritt P; Schaefer C; Agaimy A; Hartmann W; Rössig C; Fröhlich B; Bäuerle T; Dirksen U; Kuwert T; Metzler M
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1564-1575. PubMed ID: 31853559
[TBL] [Abstract][Full Text] [Related]
45. Prognostic value of 18F-FDG-PET/CT parameters in patients with pancreatic carcinoma: A systematic review and meta-analysis.
Zhu D; Wang L; Zhang H; Chen J; Wang Y; Byanju S; Liao M
Medicine (Baltimore); 2017 Aug; 96(33):e7813. PubMed ID: 28816978
[TBL] [Abstract][Full Text] [Related]
46. Prognostic value of 18F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis.
Chen L; Wu X; Ma X; Guo L; Zhu C; Li Q
Medicine (Baltimore); 2017 Feb; 96(6):e5913. PubMed ID: 28178131
[TBL] [Abstract][Full Text] [Related]
47. Clinical value of baseline
Reyes Marlés RH; Navarro Fernández JL; Puertas García-Sandoval JP; Santonja Medina F; Mohamed Salem L; Frutos Esteban L; Contreras Gutiérrez JF; Castellón Sánchez MI; Ruiz Merino G; Claver Valderas MA
Eur J Hybrid Imaging; 2021 Sep; 5(1):16. PubMed ID: 34476632
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
49. Metabolic Tumor Burden Assessed by Dual Time Point [
Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
[TBL] [Abstract][Full Text] [Related]
50. Prognostic values of mid-radiotherapy
Kim N; Cho H; Yun M; Park KR; Lee CG
Radiat Oncol; 2019 Feb; 14(1):27. PubMed ID: 30717809
[TBL] [Abstract][Full Text] [Related]
51. Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline
Garcia-Vicente AM; Pérez-Beteta J; Amo-Salas M; Molina D; Jimenez-Londoño GA; Soriano-Castrejón AM; Pena Pardo FJ; Martínez-González A
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):73-79. PubMed ID: 29102649
[TBL] [Abstract][Full Text] [Related]
52. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in lymph node metastases and risk stratification of endometrial carcinoma.
Liu DD; Li J; Li X; Xie L; Qin L; Peng F; Cheng MH
J Gynecol Oncol; 2019 Nov; 30(6):e89. PubMed ID: 31576685
[TBL] [Abstract][Full Text] [Related]
53. Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer.
Nakanishi K; Nakamura S; Sugiyama T; Kadomatsu Y; Ueno H; Goto M; Ozeki N; Fukui T; Iwano S; Chen-Yoshikawa TF
BMC Cancer; 2021 Sep; 21(1):983. PubMed ID: 34474680
[TBL] [Abstract][Full Text] [Related]
54. The Prognostic Value of Baseline 18F-FDG PET/CT in Human Papillomavirus-Positive Versus Human Papillomavirus-Negative Patients With Oropharyngeal Cancer.
Gouw ZAR; La Fontaine MD; van Kranen S; van de Kamer JB; Vogel WV; van Werkhoven E; Sonke JJ; Al-Mamgani A
Clin Nucl Med; 2019 May; 44(5):e323-e328. PubMed ID: 30889002
[TBL] [Abstract][Full Text] [Related]
55. Prognostic Impact of Pretreatment 2-[
Albano D; Dondi F; Mazzoletti A; Bellini P; Giubbini R; Bertagna F
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34069203
[No Abstract] [Full Text] [Related]
56. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
[TBL] [Abstract][Full Text] [Related]
57. Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in
Higuchi T; Fujimoto Y; Ozawa H; Bun A; Fukui R; Miyagawa Y; Imamura M; Kitajima K; Yamakado K; Miyoshi Y
Ann Surg Oncol; 2019 Jul; 26(7):2175-2183. PubMed ID: 30941655
[TBL] [Abstract][Full Text] [Related]
58. The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.
Kiamanesh Z; Ayati N; Sadeghi R; Hawkes E; Lee ST; Scott AM
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4661-4676. PubMed ID: 35932329
[TBL] [Abstract][Full Text] [Related]
59. Molecular subtype classification of breast cancer using established radiomic signature models based on
Liu J; Bian H; Zhang Y; Gao Y; Yin G; Wang Z; Li X; Ma W; Xu W
Front Biosci (Landmark Ed); 2021 Aug; 26(9):475-484. PubMed ID: 34590460
[No Abstract] [Full Text] [Related]
60. [
Xu HQ; Song LJ; Ding CY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1690-1700. PubMed ID: 38071047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
